The PIC/S Inspectors Working Group is preparing to finalize the EMA Annex 1, Manufacture of Sterile Medicinal Product, guidance/GMPs. The revision, an overhaul of the 2008 version of the annex, attempts to clarify many issues and concerns specific to aseptic processing of sterile medicinal products.
This article identifies and explores several challenges that permeate the industry as a whole — each of which poses a unique and very real challenge to the fully effective implementation of a quality risk management (QRM) program. It also explains the ways in which these challenges can sabotage QRM efforts.
Following the publication of ICH Q9, industry eagerly embraced the opportunity to share ideas and best practices related to QRM. This article focuses on selected publications addressing general, rather than specific, applications of QRM.
Quality risk management (QRM) is not a concept to be applied in a vacuum. Rather, it is a discipline that provides the most value when used throughout the product life cycle.
ICH Q9, Quality Risk Management, represents the first internationally recognized guideline specifically addressing QRM for the pharmaceutical and biopharmaceutical industries, offering an overview of general QRM principles, an example of a risk management life cycle, discussion around the activities that occur in each life cycle phase, and a list of risk tools and quality system areas to which QRM can be applied.
This is the second in a series of six articles intended to provide a holistic primer on the field of quality risk management (QRM). This installment reviews the origins of pharmaceutical risk management and regulatory thinking that led to the establishment of QRM as a unique discipline in pharmaceutical development and manufacturing.
This article marks the first of a series intended to provide a holistic primer on the field of quality risk management (QRM). The series will explore topics including the various types of risks associated with medicinal products, the role of risk management in pharmaceutical and biopharmaceutical regulation, QRM principles and practices, the role of QRM across the product life cycle, primary literature sources for QRM, and common challenges associated with QRM implementation.